JP2016513696A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513696A5
JP2016513696A5 JP2016502433A JP2016502433A JP2016513696A5 JP 2016513696 A5 JP2016513696 A5 JP 2016513696A5 JP 2016502433 A JP2016502433 A JP 2016502433A JP 2016502433 A JP2016502433 A JP 2016502433A JP 2016513696 A5 JP2016513696 A5 JP 2016513696A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
optionally
compound
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502433A
Other languages
English (en)
Japanese (ja)
Other versions
JP6534650B2 (ja
JP2016513696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027428 external-priority patent/WO2014152518A2/en
Publication of JP2016513696A publication Critical patent/JP2016513696A/ja
Publication of JP2016513696A5 publication Critical patent/JP2016513696A5/ja
Application granted granted Critical
Publication of JP6534650B2 publication Critical patent/JP6534650B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502433A 2013-03-14 2014-03-14 ロイコトリエンa4加水分解酵素の阻害剤 Expired - Fee Related JP6534650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781193P 2013-03-14 2013-03-14
US61/781,193 2013-03-14
PCT/US2014/027428 WO2014152518A2 (en) 2013-03-14 2014-03-14 Inhibitors of leukotriene a4 hydrolase

Publications (3)

Publication Number Publication Date
JP2016513696A JP2016513696A (ja) 2016-05-16
JP2016513696A5 true JP2016513696A5 (enExample) 2017-04-13
JP6534650B2 JP6534650B2 (ja) 2019-06-26

Family

ID=51581716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502433A Expired - Fee Related JP6534650B2 (ja) 2013-03-14 2014-03-14 ロイコトリエンa4加水分解酵素の阻害剤

Country Status (10)

Country Link
US (2) US9777006B2 (enExample)
EP (1) EP2970309A4 (enExample)
JP (1) JP6534650B2 (enExample)
KR (1) KR20150127246A (enExample)
AU (1) AU2014239567B2 (enExample)
BR (1) BR112015022864A8 (enExample)
CA (1) CA2906084A1 (enExample)
MX (1) MX2015011678A (enExample)
RU (1) RU2678196C2 (enExample)
WO (1) WO2014152518A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス,インコーポレイテッド ロイコトリエンa4加水分解酵素を阻害する方法
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
CN104530153A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一类苯基s-葡萄糖苷衍生物、其制备方法和在医药上的用途
CN104530151A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一种含硝基苯s-葡萄糖苷结构的化合物及其用途
CN104530152A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一种含丙烯腈基和三氟甲氧苯基o-葡萄糖苷结构化合物及用途
AU2017371353B2 (en) 2016-12-09 2022-02-03 Celltaxis, Llc Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
MY210039A (en) 2018-10-30 2025-08-22 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6815872A (enExample) 1967-11-22 1969-05-27
JPS5614663B2 (enExample) 1971-08-21 1981-04-06
US4582833A (en) 1984-04-16 1986-04-15 American Cyanamid Company 2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines
US4576943A (en) 1984-10-09 1986-03-18 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines
US5308852A (en) 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
PT880363E (pt) 1996-02-13 2002-12-31 Searle & Co Combinacoes com efeitos imunossupressores cntendo um inibidor da ciclooxigenase-2 e um inibidor da hidrolase do leucotrieno a4
US5952349A (en) 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
US6309561B1 (en) 1997-12-24 2001-10-30 3M Innovative Properties Company Liquid crystal compounds having a chiral fluorinated terminal portion
US6380203B1 (en) * 1998-01-14 2002-04-30 Merck & Co., Inc. Angiogenesis inhibitors
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US6924313B1 (en) 1999-09-23 2005-08-02 Pfizer Inc. Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
US6875483B2 (en) 2000-07-06 2005-04-05 Fuji Photo Film Co., Ltd. Liquid crystal composition comprising liquid crystal molecules and alignment promoter
WO2002064211A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
US7012075B2 (en) 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2826011B1 (fr) 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US20050143372A1 (en) 2001-10-30 2005-06-30 Shomir Ghosh Compounds, pharmaceutical compositions and methods of use therefor
CA2502359A1 (en) 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004058683A2 (en) 2002-12-20 2004-07-15 Migenix Corp. Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto
CA2521000A1 (en) 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. Preventive and/or therapeutic agent for neuropathic pain
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
UA87986C2 (uk) 2003-07-28 2009-09-10 Янссен Фармацевтика Н.В. Бензімідазольні, бензтіазольні та бензоксазольні похідні і їх застосування як lta4h модуляторів
US20050272051A1 (en) 2003-09-17 2005-12-08 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
US7674899B2 (en) 2004-02-04 2010-03-09 Neurosearch A/S Dimeric azacyclic compounds and their use
WO2006033795A2 (en) * 2004-09-17 2006-03-30 Wyeth Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
JP2008536825A (ja) 2005-03-31 2008-09-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ フェニルおよびピリジルlta4hモジュレータ
GB0514018D0 (en) 2005-07-07 2005-08-17 Ionix Pharmaceuticals Ltd Chemical compounds
US7402684B2 (en) 2005-09-21 2008-07-22 Decode Genectics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
DE102005049954A1 (de) 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
US7820821B2 (en) 2006-02-10 2010-10-26 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
WO2008046756A1 (en) 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
MY147320A (en) 2006-12-14 2012-11-30 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2173735B1 (en) 2007-07-02 2012-01-11 F. Hoffmann-La Roche AG Imidazole derivatives as ccr2 receptor antagonists
BRPI0820665A2 (pt) 2007-12-12 2018-05-29 Astrazeneca Ab compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
CN101959889A (zh) * 2008-02-26 2011-01-26 诺瓦提斯公司 作为cxcr2抑制剂的杂环化合物
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2010011912A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Trpv4 antagonists
CN102030700B (zh) 2009-09-30 2016-06-01 中国医学科学院药物研究所 苯甲酰胺基羧酸类化合物及其制法和药物用途
AU2010313402B2 (en) 2009-10-30 2015-12-03 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
MX2012006484A (es) 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
US8609669B2 (en) * 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
CA2829993A1 (en) 2011-03-15 2012-09-20 Rib-X Pharmaceuticals, Inc. Antimicrobial agents
CA2837079A1 (en) 2011-05-23 2012-11-29 Janssen Pharmaceutica Nv Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
CN103159742B (zh) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
US9006235B2 (en) * 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス,インコーポレイテッド ロイコトリエンa4加水分解酵素を阻害する方法
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase

Similar Documents

Publication Publication Date Title
JP2016513696A5 (enExample)
JP2016516043A5 (enExample)
JP2016513681A5 (enExample)
JP2016506962A5 (enExample)
JP2015522650A5 (enExample)
JP2017509586A5 (enExample)
JP2015537020A5 (enExample)
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
JP2014503574A5 (enExample)
JP2016506961A5 (enExample)
JP2013542261A5 (enExample)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
EA201490418A1 (ru) Новые макроциклические соединения в качестве ингибиторов фактора xia
MX2017010477A (es) Compuestos triciclicos y usos de los mismos en medicina.
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
RU2015147447A (ru) Производные доластатина 10 и ауристатинов
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201001094A1 (ru) Производные индазола
JP2015521195A5 (enExample)
JP2019535723A5 (enExample)